CD8A and melanoma: Based on this evidence, the current preclinical and clinical studies regarding melanoma immunotherapy are centred on the administration of DCs or CD8+ cells in the form of DC vaccines or adoptive T cell transfer, preceded by radiotherapy or chemotherapy to induce lymphodepletion and the ensuing elimination of immunosuppressive MDSCs and Tregs [49–52].